Ursodeoxycholic acid effectively kills drug-resistant gastric cancer cells through induction of autophagic death

Oncology Reports

Volumn 34, Issue 3, 2015, Pages 1261-1268

  Lim, Sung Chul ^a   Han, Song Iy ^b  

^a Chosun University College of Medicine   (South Korea)

^b Chosun University   (South Korea)

Author keywords

Autophagy; Drug resistance; Gastric carcinoma cells; Ursodeoxycholic acid

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CISPLATIN; ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; ORGANIC ANION TRANSPORTER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR SUPPRESSOR PROTEIN; URSODEOXYCHOLIC ACID; ATG5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; TNFRSF10B PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIPID RAFT; PRIORITY JOURNAL; STOMACH CANCER; SURVIVAL RATE; UPREGULATION; BIOSYNTHESIS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANTIGENS, CD95; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; URSODEOXYCHOLIC ACID;

EID: 84937207192     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4076     Document Type: Article

References (30)

1. Brozovic A, Fritz G, Christmann M, Zisowsky J, Jaehde U, Osmak M and Kaina B: Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer 112: 974-985, 2004.
2. Komatsu M, Sumizawa T, Mutoh M, Chen ZS, Terada K, Furukawa T, Yang XL, Gao H, Miura N, Sugiyama T, et al: Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 60: 1312-1316, 2000.
3. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S and Kuwano M: A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56: 4124-4129, 1996.
4. Zhu HJ, Wang JS, Guo QL, Jiang Y and Liu GQ: Reversal of P-glycoprotein mediated multidrug resistance in K562 cell line by a novel synthetic calmodulin inhibitor, E6. Biol Pharm Bull 28: 1974-1978, 2005.
5. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279, 2006.
6. Wang J, Zhou JY and Wu GS: ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Res 67: 11933-11941, 2007.
7. Choi CH, Kim HS, Kweon OS, Lee TB, You HJ, Rha HS, Jeong JH, Lim DY, Min YD, Kim MS, et al: Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines. Mol Cells 10: 38-46, 2000.
8. Xu Z, Chen ZP, Malapetsa A, Alaoui-Jamali M, Bergeron J, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, et al: DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 13: 511-519, 2002.
9. Alberts DS, Martínez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, Guillen J, Krutzsch M, Batta AK, Salen G, et al; Phoenix and Tucson Gastroenterologist Networks: Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 97: 846-853, 2005.
10. Khare S, Cerda S, Wali RK, von Lintig FC, Tretiakova M, Joseph L, Stoiber D, Cohen G, Nimmagadda K, Hart J, et al: Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer. Cancer Res 63: 3517-3523, 2003.
11. Lim SC, Duong HQ, Choi JE, Lee TB, Kang JH, Oh SH and Han SI: Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells. Carcinogenesis 32: 723-731, 2011.
12. Lim SC, Duong HQ, Parajuli KR and Han SI: Pro-apoptotic role of the MEK/ERK pathway in ursodeoxycholic acid-induced apoptosis in SNU601 gastric cancer cells. Oncol Rep 28: 1429-1434, 2012.
13. Iwasaki I, Sugiyama H, Kanazawa S and Hemmi H: Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles. Cancer Chemother Pharmacol 49: 438-444, 2002.
14. Sun CL and Chao CC: Cross-resistance to death ligand-induced apoptosis in cisplatin-selected HeLa cells associated with overexpression of DDB2 and subsequent induction of cFLIP. Mol Pharmacol 67: 1307-1314, 2005.
15. Xu H, Choi SM, An CS, Min YD, Kim KC, Kim KJ and Choi CH: Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines. Biochem Biophys Res Commun 328: 618-622, 2005.
16. Hengartner MO: The biochemistry of apoptosis. Nature 407: 770-776, 2000.
17. Martinou JC and Green DR: Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2: 63-67, 2001.
18. Tsujimoto Y: Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol 195: 158-167, 2003.
19. Zeuner A, Pedini F, Signore M, Ruscio G, Messina C, Tafuri A, Girelli G, Peschle C and De Maria R: Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. Blood 107: 3495-3502, 2006.
20. Müllauer L, Gruber P, Sebinger D, Buch J, Wohlfart S and Chott A: Mutations in apoptosis genes: A pathogenetic factor for human disease. Mutat Res 488: 211-231, 2001.
21. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC and Zunino F: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-562, 1996.
22. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, Fan Y, et al: Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10: 51-64, 2006.
23. Hippert MM, O'Toole PS and Thorburn A: Autophagy in cancer: Good, bad, or both? Cancer Res 66: 9349-9351, 2006.
24. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H and Levine B: Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402: 672-676, 1999.
25. Syntichaki P and Tavernarakis N: The biochemistry of neuronal necrosis: Rogue biology? Nat Rev Neurosci 4: 672-684, 2003.
26. Vakkila J and Lotze MT: Inflammation and necrosis promote tumour growth. Nat Rev Immunol 4: 641-648, 2004.
27. Zong WX and Thompson CB: Necrotic death as a cell fate. Genes Dev 20: 1-15, 2006.
28. Bernales S, McDonald KL and Walter P: Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response. PLoS Biol 4: e423, 2006.
29. Eisenberg-Lerner A, Bialik S, Simon HU and Kimchi A: Life and death partners: Apoptosis, autophagy and the cross-talk between them. Cell Death Differ 16: 966-975, 2009.
30. Moretti L, Cha YI, Niermann KJ and Lu B: Switch between apoptosis and autophagy: Radiation-induced endoplasmic reticulum stress? Cell Cycle 6: 793-798, 2007.